Issue 14 · Nov 2–8, 2026Agent Age News magazine · Other editions · Method · HU / ENG

How AI is affecting healthcare, medicine and drug development, curated weekly

regulation · United States

AHA, AMA, ATA and radiology groups respond to FDA plan for generative AI medical devices

Oct 19, 2026 · Issue 12 · 25 sources, 25 articles

The AHA, the AMA, ATA Action and radiology societies submitted written comments in mid-October on the FDA's regulatory plan for generative AI-enabled medical devices. ATA highlighted two-dimensional risk classification, PCCPs and manufacturer accountability; an FDA official said such devices should be evaluated like physicians, and CDRH called the topic a White House priority, while FDA and state regulation diverge.

Who is affected and how

medtech company
Risk-based classification, PCCPs and manufacturer accountability bear directly on the authorization plans for generative AI products.
doctor
The professional bodies' proposals may also shape how clinician responsibility and oversight are divided.
hospital manager
Diverging FDA and state rules create procurement and compliance risk for generative AI tools.
health policy
The conflict between state and federal levels creates an unclear regulatory environment.

Narrative: AI must be licensed as a doctor

Sources

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.